The appointment of Michael Kaseta, with his extensive experience in corporate finance and biopharma commercialization, could positively impact Heron Therapeutics by enhancing its strategic direction and financial management. This is likely to be viewed favorably by investors, potentially leading to a positive short-term impact on the stock price.